Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 8/20 | 0.65 |
| ▸ | JAK1 | P23458 | 5/20 | 0.65 |
| ▸ | JAK2 | O60674 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.64 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.64 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154853 | 0.83 | TYK2 (0.71) | TYK2JAK1JAK2CYP3A4TAS1R3 | |
| SCHEMBL678659 | 0.82 | KMT2A (0.67) | TYK2JAK1JAK2CYP3A4TAS1R3 | |
| SCHEMBL7384072 | 0.82 | TYK2 (0.65) | TYK2JAK1JAK2CYP3A4TAS1R3 | |
| SCHEMBL14532180 | 0.82 | TYK2 (0.65) | TYK2JAK1JAK2CYP3A4TAS1R3 | |
| SCHEMBL95731 | 0.81 | SMO (0.71) | TYK2JAK2KMT2AMAPTRAB9A | |
| SCHEMBL6602761 | 0.79 | TYK2 (0.61) | TYK2JAK1JAK2CYP3A4TAS1R3 | |
| SCHEMBL13058075 | 0.79 | TYK2 (0.61) | TYK2JAK1JAK2CYP3A4TAS1R3 | |
| SCHEMBL6601710 | 0.79 | TYK2 (0.61) | TYK2JAK1JAK2CYP3A4TAS1R3 | |
| SCHEMBL6740620 | 0.79 | TYK2 (0.65) | TYK2JAK1JAK2CYP3A4TAS1R3 | |
| SCHEMBL701132 | 0.78 | TAS1R3 (1.00) | TYK2JAK1JAK2CYP3A4TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| CN-101489555-A | Nf-kappa | OTSUKA PHARMA CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| US-6579889-B2 | Alzheier's diseases; antiallergens; vision defects; antihistamines; skin disorders | MERCK & CO., INC. | 2003-06-17 | — | — | US | disclosed |
| US-6420418-B1 | INHIBITION AND PREVENTION OF LEUKOCYTE ADHESION; USED TO TREAT ADHESION-MEDIATED DISEASES SUCH AS ASTHMA, ALLERGIC RHINITIS, MULTIPLE SCLEROSIS; ATHEROSCLEROSIS, AND INFLAMMATORY BOWEL DISEASE | MERCK & CO., INC. | 2002-07-16 | — | — | US | disclosed |
| US-6403584-B1 | CONJUNCTIVITIS, ALLERGIC RHINITIS, ALZHEIMER'S DISEASE, ASTHMA, ATHEROSCLEROSIS, AUTOLOGOUS BONE MARROW TRANSPLANTATION, ANTIINFLAMMATORY, ETC | MERCK & CO., INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020019419-A1 | Substituted isonipecotyl derivatives as inhibitors of cell adhesion | MERCK & CO., INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001012183-A1 | HETEROCYCLE AMIDES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | TYK2 1109/4885JAK1 275/4885JAK2 114/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | TYK2 609/4885JAK1 95/4885JAK2 92/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | TYK2 609/4885JAK1 95/4885JAK2 92/4885 |
| US-20020019419-A1 | Substituted isonipecotyl derivatives as inhibitors of cell adhesion | VCAM1, ICAM1, CD4 | TYK2 2391/4885JAK1 2987/4885JAK2 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.